## GILD: Gilead Sciences, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.5% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($115.53)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Lombard Odier Asset Management Switzerland SA Raises Position in Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251209T140805 | Somewhat-Bullish | Relevance: 100%
-  Lombard Odier Asset Management Switzerland SA increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 24.6% in the second quarter, bringing its total holdings to 53,312 shares valued at $5,911,000. This move aligns with several other institutional investors who have recently modified their positions in the biopharmaceutical company, while some insiders have sold shares. Analysts maintain a "Moderate Buy" rating for Gilead Sciences with an average target price of $130.65.

**2. California Public Employees Retirement System Sells 512,416 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251207T190836 | Neutral | Relevance: 99%
-  The California Public Employees Retirement System recently reduced its stake in Gilead Sciences by 10.9%, selling 512,416 shares, though still retaining over 4.1 million shares valued at approximately $462.9 million. This sale occurred while Gilead reported strong Q3 earnings, exceeding analyst expectations for both EPS and revenue, and announced a quarterly dividend of $0.79 per share. Other institutional investors showed mixed activity, with some increasing their positions in Gilead, while company insiders also sold shares.

**3. 1832 Asset Management L.P. Makes New $4.69 Million Investment in Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251206T081341 | Somewhat-Bullish | Relevance: 99%
-  1832 Asset Management L.P. has made a new $4.69 million investment in Gilead Sciences, Inc., acquiring 42,300 shares in the biopharmaceutical company during the second quarter. Other institutional investors have also adjusted their holdings, while company insiders have recently sold shares. Analyst ratings for Gilead Sciences are generally positive, with a "Moderate Buy" consensus and an average price target of $130.65.

**4. Federated Hermes Inc. Sells 1,885,664 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251207T121259 | Somewhat-Bullish | Relevance: 98%
-  Federated Hermes Inc. reduced its stake in Gilead Sciences, Inc. by 38.7% in the second quarter, selling 1,885,664 shares while retaining 2,980,646 shares valued at $330.46 million. Despite this sale, analysts remain largely positive on Gilead, with a "Moderate Buy" consensus rating and an average price target of $130.65. The biopharmaceutical company recently beat quarterly EPS estimates and announced a quarterly dividend of $0.79 per share.

**5. Gilead Sciences, Inc. $GILD Shares Sold by Baird Financial Group Inc.**
- Source: MarketBeat | 20251207T082435 | Somewhat-Bullish | Relevance: 98%
- Baird Financial Group Inc. reduced its stake in Gilead Sciences (NASDAQ:GILD) by 4.7% during the second quarter, selling 8,323 shares and maintaining 170,425 shares valued at approximately $18.9 million. This adjustment comes as Gilead reported strong Q3 earnings, exceeding analyst expectations with $2.47 EPS and $7.77 billion in revenue, and forecasting an FY 2025 EPS between $8.05 and $8.25. Despite insider selling by CEO Daniel O'Day and other executives, institutional investors collectively own 83.67% of the company's stock, and Gilead declared a quarterly dividend of $0.79 per share.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | Needham | $140 | $133 | +5% |
| 2025-11-13 | Scotiabank | $140 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | Needham | main | Buy |
| 2025-11-13 | Scotiabank | init | Sector Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($10.00M) |
| Sells | 14 ($7.11M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (-0.3%)
- Blackrock Inc.: 9.4% (+1.2%)
- FMR, LLC: 4.9% (+0.6%)
- State Street Corpora: 4.8% (-0.2%)
- Capital World Invest: 3.6% (-2.4%)

### Key Risks

1. Insider selling cluster: $7.1M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.21 indicates undervaluation relative to growth. Forward P/E 13.9x stretched relative to 7% growth. Quality metrics strong (ROE 41%, ROA 13%, margin 28%). Balance sheet: $4.0B free cash flow. Analyst sentiment positive (1 raises, avg +5%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $150.4B |
| Beta | 0.33 |
| 52W Range | $88.57 - $128.70 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.21 |
| Forward P/E | 13.9 |
| Current P/E | 14.8 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.6% over 5 days). Below STRENGTH zone by 6.5pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.07x) but short-term weakness (below SMA20). MACD histogram bearish (-0.80), momentum weakening. RSI neutral at 44.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.51% (CS: 18) | Weak |
| RSI_14 | 44.5 | Neutral |
| MACD Histogram | -0.80 | Bearish |
| vs SMA20 | 0.974x | Below |
| vs SMA50 | 1.003x | Above |
| vs SMA200 | 1.072x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $121.19
- **Stop Loss:** $115.53 (4.7% risk)
- **Target:** $126.85 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 88
- **Position Value:** $10,664.72
- **Portfolio %:** 10.66%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-10 (Est: $1.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.14 | $2.47 | +15.7% |
| 2025Q2 | $1.96 | $2.01 | +2.7% |
| 2025Q1 | $1.78 | $1.81 | +1.9% |
| 2024Q4 | $1.70 | $1.90 | +11.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*